Medically reviewed by Drugs.com. Last updated on March 17, 2021.
In 2002, Mac OS X v10.2, code-named 'Jaguar', was released with a brand new logo. The logo was an 'X' that had a jaguar print instead of the previous blue 'X'. This was the first release of Mac OS X in which the OS was actually marketed using the code name, Jaguar. Following v10.2, Mac OS X Panther was released in 2003. For others, there's SheepShaver, a PowerPC emulator capable of running Mac OS 9.0.4 down to Mac OS 7.5.2 and there's Basilisk II, a 68k emulator, capable of running Mac OS (8.1 to 7.0). For everything older than System 7, you will need a Mac Plus emulator like Mini vMac NEW!
Applies to the following strengths: 12 mg; 6 mg; 2 mg; 4 mg; 8 mg; 0.25 mg; 0.5 mg; 1 mg; 5 mg; 3 mg; 0.25 mg-0.5 mg-1 mg Rumble (itch) mac os.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Parkinson's Disease
Immediate-release tablets:
Initial: 0.25 mg orally three times daily
After 1 week, the dose may be titrated up in weekly increments based on individual efficacy and tolerability:
Week 2: give 0.5 mg orally 3 times daily
Week 3: give 0.75 mg orally 3 times daily
Week 4: give 1 mg orally 3 times daily
After week 4, increase by 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, then increase by 3 mg/day on a weekly basis up to a maximum daily dose of 24 mg
Maximum Dose: 8 mg orally three times a day
Extended-release tablets:
Initial: 2 mg orally once daily for 1 to 2 weeks, followed by increases of 2 mg/day at 1-week or longer intervals, depending on therapeutic response and tolerability
Maximum dose: 24 mg orally once a day
Patients may switch from immediate-release to extended-release: The initial dose of extended-release tablet should most closely match the total daily dose of immediate-release formulation. Following conversion, adjust dose depending on response and tolerability.
Comments:
-If significant interruption in therapy occurs, retitration may be necessary; upon discontinuation, this drug should be gradually tapered over a 7-day period.
-The extended-release tablet is designed to release medication over a 24-hour period, if rapid gastrointestinal transit occurs, and tablet residue is observed in the stool, there is a risk of incomplete release of medication,
Use: For the treatment of Parkinson's disease.
Usual Adult Dose for Restless Legs Syndrome
Immediate-release tablets:
Initial: 0.25 mg orally once a day on Day 1 and Day 2
Dose titration: May titrate as follows based on individual efficacy and tolerability:
Days 3 to 7: give 0.5 mg orally once a day
-Week 2: give 1 mg orally once a day
-Week 3: give 1.5 mg orally once a day
-Week 4: give 2 mg orally once a day
-Week 5: give 2.5 mg orally once a day
-Week 6: give 3 mg orally once a day
-Week 7: give 4 mg orally once a day
Maximum Dose: 4 mg orally once a day
Comments:
-Take 1 to 3 hours before bedtime.
-In clinical trials, this drug was not tapered prior to discontinuation.
Use: For the treatment of moderate to severe Restless Legs Syndrome.
Renal Dose Adjustments
Parkinson's disease:
Moderate renal impairment (CrCl 30 to 50 mL/mi): No dosage adjustment is necessary
Severe renal impairment without regular dialysis: No data available
Restless Leg Syndrome:
Moderate renal impairment (CrCl 30 to 50 mL/min): No dosage adjustment is necessary
Severe renal impairment without regular dialysis: No data available
Liver Dose Adjustments
Dose adjustments may be required; however, no specific guidelines have been suggested. Caution is recommended.
Dose Adjustments
Doses are individually titrated based on efficacy and tolerability.
Parkinson's disease:
-If this drug is administered as adjunct therapy to levodopa, the concurrent dose of levodopa may be decreased gradually as tolerated; the average dose reduction of levodopa was 31% and 34% with immediate-release and extended-release tablets, respectively.
Drug interruption:
-If significant interruption in therapy occurs, this drug may need to be retitrated.
Drug discontinuation:
-Immediate-release tablets: Reduce the frequency of administration from 3 times a day to 2 times a day for 4 days, then once a day for 3 days, prior to discontinuation.
-Extended-release tablets: Gradually discontinue over a 7-day period
Precautions
Safety and efficacy of ropinirole have not been established in patients younger than 18 years.
Safety and efficacy of the extended-release product have not been established in patients with Restless Legs Syndrome (RLS).
Consult WARNINGS section for additional precautions.
Dialysis
Peritoneal dialysis: Data not available
End stage renal disease (ESRD) on hemodialysis:
Parkinson's disease, Immediate-release:
-Initial dose: 0.25 mg orally 3 times a day
-Dose titration should be based on tolerability and need for efficacy
-Maximum dose: 6 mg orally 3 times a day
Parkinson's disease, Extended-release:
-Initial dose: 2 mg orally once a day
-Dose titration should be based on tolerability and need for efficacy
-Maximum dose: 18 mg orally once a day
Restless Leg Syndrome:
-Initial dose: 0.25 mg orally once a day
-Dose titration should be based on tolerability and need for efficacy
-Maximum dose: 3 mg orally once a day
Comments: Supplemental doses after dialysis are not required.
Other Comments
Dialysis
Peritoneal dialysis: Data not available
End stage renal disease (ESRD) on hemodialysis:
Parkinson's disease, Immediate-release:
-Initial dose: 0.25 mg orally 3 times a day
-Dose titration should be based on tolerability and need for efficacy
-Maximum dose: 6 mg orally 3 times a day
Parkinson's disease, Extended-release:
-Initial dose: 2 mg orally once a day
-Dose titration should be based on tolerability and need for efficacy
-Maximum dose: 18 mg orally once a day
Restless Leg Syndrome:
-Initial dose: 0.25 mg orally once a day
-Dose titration should be based on tolerability and need for efficacy
-Maximum dose: 3 mg orally once a day
Comments: Supplemental doses after dialysis are not required.
Other Comments
Administration advice:
-May take with or without food
-If a dose is missed, take your next dose as scheduled; do not double your next dose
-Extended-release products should be taken once a day at a similar time each day; they should not be chewed, crushed, or split
-Restless Leg Syndrome: Take once a day 1 to 3 hours before bedtime
General:
-If significant interruption to therapy occurs, this drug should be retitrated.
-Parkinson's Disease: This product should be tapered before discontinuation.
-Restless Legs Syndrome: This drug was not tapered to discontinuation during clinical trials.
Monitoring:
-Cardiovascular: Monitor for signs and symptoms of orthostatic hypotension, particularly during dose escalation; consider blood pressure monitoring at the start of treatment, especially in patients with significant cardiovascular disease.
-Nervous System: Monitor for somnolence and drowsiness
-Dermatologic: Monitor for melanomas; consider periodic skin examinations by dermatologists.
-Psychiatric: Question patients about new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges.
Patient advice:
-This drug frequently causes drowsiness; patients should not drive a car or operate machinery or other potentially dangerous activities until it is determined how this drug affects their mental and/or motor performance.
-Patients should be instructed to report episodes of sudden onset of sleep, new or worsening dyskinesia, new or worsening compulsive behaviors and/or unusual urges.
-Patients should be instructed to report changes in the size, shape, or color of moles on their skin and should have their skin checked on a regular basis for melanomas.
-Patients should be aware that this drug may cause orthostatic blood pressure changes including fainting and dizziness and patients should be advised to avoid standing rapidly after sitting or lying down.
-Patients should speak to their physician or health care provider if they become pregnant, intend to become pregnant, or are breastfeeding.
More about ropinirole
- During Pregnancy or Breastfeeding
Consumer resources
- Other brands
- Requip, Requip XL
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
MAC lung disease is an infection caused a group of bacteria called Mycobacterium avium complex (MAC). MAC includes two closely related species, Mycobacterium avium and Mycobacterium intracellulare, and may also be referred to as MAI. MAC is one of a large group of nontuberculous mycobacteria (NTM), and the most common cause of NTM lung disease in the U.S.
Legs Mac Os X
MAC organisms are common in soil and water and are easily inhaled during daily activities. Most of the time they cause no harm, but they can cause infection in groups with certain risk factors. These groups include people living with lung disease such as bronchiectasisandCOPD, and people with a weakened immune system because of an autoimmune disorder or medical treatment such as drugs that compromise immunity. Postmenopausal women and people over 65 years old are also more likely to develop MAC lung disease than the general public.
Key Facts
- MAC infection is a serious condition that can cause damage to the lungs.
- MAC infection is not contagious.
- Common signs and symptoms of MAC lung disease include fatigue, chronic cough, shortness of breath, night sweats, coughing up blood and weight loss. Symptoms may persist or worsen despite being treated for another lung condition.
- MAC lung disease diagnosis includes a clinical exam, a chest x-ray or CT scan and a lab culture of sputum from your lungs.
- MAC lung disease treatment usually involves a combination of antibiotics taken over an extended period of time.
- In addition to lung disease, MAC can also cause an infection that spreads throughout the body, usually in people with advanced AIDS, called disseminated MAC disease, as well as a swelling in the lymph nodes called lymphadenitis that is most common in young children.
Legs Most Beautiful Of All Time
For more information about MAC lung disease symptoms, diagnosis and treatment, see our pages on nontuberculous mycobacterial lung disease.
Legs Mac Os Download
Development of this educational content was supported by a collaborative sponsorship from Insmed Incorporated.
